PTC Therapeutics announced pricing of $500 million in 0% convertible senior notes due 2031, with net proceeds to refinance $222 million of 2026 convertible notes. The offering includes a 40% conversion premium and represents a refinancing strategy to extend debt maturity while maintaining financial flexibility.